Generic Name Pharmacologic General Indications Concentrations CNS: Restlessness, apprehension, Before

Terbutaline sulfate Class In low doses, acts relatively - Prophylaxis and - Hypersensitivity to anxiety, fear, CNS stimulation, - Observe 15 rights of drug
Beta2-selective selectively at beta2-adrenergic treatment of bronchial terbutaline hyperkinesia, insomnia, tremor, administration.
Trade Name adrenergic receptors to cause bronchodilation asthma and reversible - Tachyarrhythmias, drowsiness, irritability, weakness, - Reduce dosage with hepatic or
Brethine antagonist and relax the pregnant uterus; bronchospasm that may tachycardia caused by vertigo, headache, seizures renal failure.
At higher doses, beta2 selectively is occur with bronchitis and digitalis intoxication - Assess for hypersensitivity to drug
Minimum Dose Therapeutic Class lost and the drug acts at beta1 emphysema, in patients - General anesthesia CV: Cardiac arrhythmias, - Assess for any contraindications t
5 mg at 6-hr Antasthmatic, 12 yr and older with halogenated palpitations, angina pain, changes in the drug.
receptors to cause typical
intervals tid Bronchodilator, sympathomimetic cardiac effects. - Unlabeled use: Tocolytic hydrocarbons or BP and ECG - Educate about side effects of drug
Sympathomimetic, to prevent preterm labor cyclopropane
Maximum Dose Tocolytic drug Pharmacokinetics - Unstable vasomotor GI: Nausea, vomiting, heartburn, During
15 mg/day system disorders unusual or bad taste in mouth - Use minimal doses for minimal
D: May cross placenta; enters - Labor and delivery periods of time, drug tolerance can
Pregnancy Risk
Contents - Lactation Respiratory: Respiratory occur with prolonged use.
Factor breast milk
Terbutaline sulfate M: Tissue difficulties, pulmonary edema, - Keep a beta-blocker, such as
B Precaution
coughing, bronchospasm atenolol, readily available in case
E: Urine - Diabetes, Coronary cardiac dysrhythmias occur.
Availability and
insufficiency, CAD, - For oral forms, administer with
color Route Onset Peak Duration Other: Sweating, pallor, flushing,
History of CVA, COPD water to facilitate swallowing.
- Tablets: 2.5, 5 muscle cramps, elevated LFTs
Oral 30 min 2-3 hr 4-8 hr patient, - For parenteral forms, avoid contac
mg Hyperthyroidism, with the needle.
- Injection: 1 SubQ 5-15 30-60 1.5-4 hr
History of seizure - Stay with patient throughout
min min
mg/mL disorder, whole duration of administration.
Drug Half Life Psychoneurotic
Routes of individuals,
2-4 hr After
administration Hypertension - Monitor client for at least 30
Oral
minutes.
Subcutaneous Drug interaction - Arrange for regular follow-up,
> Drug to drug including blood tests, to evaluate
- Increased likelihood of effects.
cardiac arrhythmias - Instruct to report chest pain,
with halogenated dizziness, insomnia, weakness,
hydrocarbon anesthetics tremor or irregular heartbeat, failur
- Risk of bronchospasms to respond to usual dosage.
if combined with - Instruct to take medication as
diuretics directed for the full course of
- Increased risk of therapy, even if feeling better.
hypokalemia and ECG - Do not double dose.
changes with MAOIs - Do proper documentation.
and TCAs

> Drug to food

- none reported
Source: Source: Source: Source: Source: Source: Source:
Karch, Amy: 2009 Karch, Amy: 2009 Karch, Amy: 2009 Lippincotts Nursing Drug Karch, Amy: 2009 Lippincotts Karch, Amy: 2009 Lippincotts Karch, Amy: 2009 Lippincotts Nursing Drug Karch, Amy: 2009 Lippincotts Nursing Drug
Lippincotts Nursing Drug Lippincotts Nursing Drug Guide, pp. 1125-1126 Nursing Drug Guide, pp. 1126 Nursing Drug Guide, pp. 1126 Guide, pp. 1126 Guide, pp. 1127
Guide, pp. 1125-1126 Guide, pp. 1125